U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160361) titled 'Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB' on Aug. 30.
Brief Summary: Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer worldwide, characterized by complex and variable disease progression and significant treatment challenges. Among HCC patients, tumor budding (TB) is associated with a high risk of postoperative recurrence, significantly impacting patient prognosis. Even in the current HCC pathological diagnosis "gold standard" of MVI-negative patients, TB retains excellent prognostic predictive value. TB cells reside within the peritumoral stroma, where dens...